Last edition
News about "Bayer"
Bayer Warns of Higher 2025 Earnings Impact from Lawsuits and Restructuring Costs
The German life sciences company now expects special items to reduce its earnings before interest, tax, depreciation, and amortisation (EBITDA) by between EUR 3.5 billion and EUR 4.0 billion, higher than the earlier forecast of EUR 2.5 billion to EUR 3.5 billion.
Bayer | 13/11/2025 | By Darshana | 433
WHO and Bayer Renew Partnership to Combat NTDs
The World Health Organization (WHO) and Bayer AG have renewed their partnership to combat Chagas disease, sleeping sickness, and taeniasis, with Bayer pledging USD 9.45 million to support WHO’s efforts through 2030.
Bayer | 06/11/2025 | By Dineshwori | 148
Bayer and Kumquat Biosciences have begun a Phase-I trial of their KRAS G12D inhibitor targeting KRAS-mutated tumors, further bolstering Bayer’s precision oncology pipeline across pancreatic, colorectal, and lung cancers.
Bayer | 11/10/2025 | By Dineshwori | 396
The first participant has been dosed in the pivotal Phase III exPDite-2 trial of bemdaneprocel, an investigational cell therapy, while the first European participants have been enrolled in REGENERATE-PD, a Phase II trial of the gene therapy AB-1005.
Bayer | 23/09/2025 | By Darshana | 209
Tata Elxsi Opens Global Radiology Tech Hub for Bayer
The centre will serve as a global innovation hub, combining Tata Elxsi’s engineering expertise with India’s healthcare ecosystem to accelerate Bayer’s radiology solutions across key markets, including the US and EU.
Bayer | 12/09/2025 | By Dineshwori | 125
Bayer Launches Bayer Co.Lab AdVenture Platform in China
Bayer launches Co.Lab AdVenture to connect biotech startups with global VCs, accelerating early-stage innovation through its lifesciences incubator network.
Bayer | 11/09/2025 | By Dineshwori | 146
Bayer Expands Global Life Sciences Incubator With Launch Of Co.Lab AdVenture
Bayer has launched Co.Lab AdVenture, a new platform under its global life sciences incubator network, designed to connect high-potential biotech start-ups with leading venture capital partners worldwide.
Bayer | 09/09/2025 | By Darshana | 217
US FDA Accepts Gadoquatrane for Review: Bayer
Bayer has submitted New Drug Application (NDA) for low dose contrast agent gadoquatrane to seek approval for contrast-enhanced Magnetic Resonance Imaging (MRI) of the Central Nervous System (CNS) and other body regions for adults and paediatric patients including neonates.
Bayer | 27/08/2025 | By Dineshwori | 100
Alvotech and Advanz Pharma Secure European Approval for Eylea Biosimilar Mynzepli
Alvotech and its commercial partner Advanz Pharma have announced that the European Commission has granted marketing authorisation for Mynzepli (aflibercept), a biosimilar to Eylea, available in both pre-filled syringes and vials.
Bayer | 22/08/2025 | By Dineshwori | 147
Bayer Seeks US FDA Approval of gadoquatrane for MRI of CNS and Other Body Parts
Bayer has submitted a New Drug Application to the US FDA for gadoquatrane, an investigational MRI contrast agent. If approved, it would offer the lowest gadolinium dose among macrocyclic GBCAs in the US, cutting exposure by 60 percent while maintaining diagnostic efficacy.
Bayer | 18/06/2025 | By Abha | 160
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy